FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Husinka, L
   Koerner, PH
   Miller, RT
   Trombatt, W
AF Husinka, Lakyn
   Koerner, Pamela H.
   Miller, Rick T.
   Trombatt, William
TI Review of cyclin-dependent kinase 4/6 inhibitors in the treatment of
   advanced or metastatic breast cancer
SO JOURNAL OF DRUG ASSESSMENT
LA English
DT Review
DE Palbociclib; abemaciclib; ribociclib; breast cancer; cancer; side
   effects; safety; adverse events
AB Objective
   The purpose of this study is to review CDK 4/6 inhibitors used to treat metastatic breast cancer for patient safety, cost and utilization. By evaluating patient outcomes and payer influence, this study will provide critical information to aid prescribers in therapeutic decisions.
   Methods
   This retrospective cohort study included patients from a national specialty pharmacy with a diagnosis of breast cancer and received either palbociclib, abemaciclib, or ribociclib for treatment. Patients were stratified into four subgroups based on their total oncolytic regimen at the time of their first eligible study medication dispense. Pharmacy claims data were reviewed to determine cost and therapy adherence.
   Results
   The mean proportion of days covered was highest in patients on combination therapy with a hormone agent, 81.0%. While secondary insurances largely affected final patient out-of-pocket costs, final copays were significantly lower than the average wholesale price (AWP) of each CDK 4/6 inhibitor. When analyzing patient reported side effects, over 60% of the study population did not experience an adverse drug event (ADE) during the study time period. Ribociclib had the fewest number of reported side effects with abemaciclib patients reporting the most. Although reported ADE profiles were similar across all three study medications, difference in frequency should be evaluated when considering medication choice with specific comorbidities.
   Conclusion
   CDK 4/6 inhibitors have demonstrated safety and tolerability in HR-positive/HER2-negative breast cancer patients. Real world safety data and out-of-pocket patient costs in addition patient specific comorbidities should be considered when developing a treatment plan that includes a CDK 4/6 inhibitor selection.
C1 [Husinka, Lakyn; Miller, Rick T.; Trombatt, William] AllianceRx Walgreens Prime, Pittsburgh, PA USA.
   [Husinka, Lakyn; Koerner, Pamela H.] Duquesne Univ, Sch Pharm, Pittsburgh, PA 15219 USA.
RP Husinka, L (corresponding author), 106 Bookbinder Cir, Pittsburgh, PA 15212 USA.
EM Lakyn.husinka@gmail.com
CR ACS, 2020, BREAST CANC COMM BRE
   [Anonymous], 2020, CDK4 6 INH REACH NEW
   [Anonymous], 2019, HORM THER BREAST CAN
   [Anonymous], 2020, BREAST CANC
   Finn RS, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.507
   Foulon V, 2011, ACTA CLIN BELG, V66, P85, DOI 10.2143/ACB.66.2.2062525
   Hansen LA, 2012, J HEMATOL ONCOL PHAR
   Im SA, 2019, NEW ENGL J MED, V381, P307, DOI 10.1056/NEJMoa1903765
   IQVIA Institute for Human Data Science, 2019, MED US SPEND US REV
   Landhuis E, 2019, SCI NEWS, V196, P8
   Marra A, 2019, NPJ BR CAN
   Marra A, 2019, NPJ BREAST CANCER, V5, DOI 10.1038/s41523-019-0121-y
   Miller TW, 2011, CANCER DISCOV, V1, P338, DOI 10.1158/2159-8290.CD-11-0101
   Paranjpe R, 2019, BREAST CANCER RES TR, V174, P297, DOI 10.1007/s10549-018-05073-z
   Spring LM, 2019, CURR ONCOL REP, V21, DOI 10.1007/s11912-019-0769-3
   Stokes M, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2373-2
   Verma S, 2016, ONCOLOGIST, V21, P1165, DOI 10.1634/theoncologist.2016-0097
   Wang F, 2019, JAMA ONCOL, V5, P1589, DOI 10.1001/jamaoncol.2019.2803
NR 18
TC 0
Z9 0
U1 10
U2 10
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1369-9474
EI 2155-6660
J9 J DRUG ASSESS
JI J. Drug Assess.
PD DEC 15
PY 2021
VL 10
IS 1
BP 27
EP 34
DI 10.1080/21556660.2020.1857103
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA PK7WD
UT WOS:000602649200001
PM 33414982
OA DOAJ Gold, Green Published
DA 2021-01-23
ER

PT J
AU Zlowocka-Perlowska, E
   Debniak, T
   Slojewski, M
   Leminski, A
   Soczawa, M
   van de Wetering, T
   Trubicka, J
   Kluzniak, W
   Wokolorczyk, D
   Cybulski, C
   Lubinski, J
AF Zlowocka-Perlowska, Elzbieta
   Debniak, Tadeusz
   Slojewski, Marcin
   Leminski, Artur
   Soczawa, Michal
   van de Wetering, Thierry
   Trubicka, Joanna
   Kluzniak, Wojciech
   Wokolorczyk, Dominika
   Cybulski, Cezary
   Lubinski, Jan
TI Recurrent PALB2 mutations and the risk of cancers of bladder or kidney
   in Polish population
SO HEREDITARY CANCER IN CLINICAL PRACTICE
LA English
DT Article
DE 509_510delGA; 172_175delTTGT mutation; PALB2; Survival
ID FANCONI-ANEMIA; BREAST-CANCER; DNA-REPAIR; GENE-MUTATIONS; PREDISPOSE;
   PARTNER; WOMEN
AB Introduction: The role of PALB2 in carcinogenesis remains to be clarified. Our main goal was to determine the prevalence of PALB2 (509_510delGA and 172_175delTTGT) mutations in bladder and kidney cancer patients from Polish population.
   Materials and methods: 1413 patients with bladder and 810 cases with kidney cancer and 4702 controls were genotyped for two PALB2 variants: 509_510delGA and 172_175delTTGT.
   Results: Two mutations of PALB2 gene were detected in 5 of 1413 (0.35%) unselected bladder cases and in 10 of 4702 controls (odds ratio [OR], 1.7; 95% CI 0.56-4.88; p = 0.52). Among 810 unselected kidney cancer cases two PALB2 mutations were reported in two patients (0,24%) (odds ratio [OR], (OR = 1.2; 95% CI 0.25-5.13; p = 0.84). In cases with mutations in PALB2 gene cancer family history was negative.
   Conclusion: We found no difference in the prevalence of recurrent PALB2 mutations between cases and healthy controls. The mutations in PALB2 gene seem not to play a major role in bladder and kidney cancer development in Polish patients.
C1 [Zlowocka-Perlowska, Elzbieta; Debniak, Tadeusz; Kluzniak, Wojciech; Wokolorczyk, Dominika; Cybulski, Cezary; Lubinski, Jan] Pomeranian Med Univ, Dept Genet & Pathol, Int Hereditary Canc Ctr, Unii Lubelskiej 1, PL-71252 Szczecin, Poland.
   [Slojewski, Marcin; Leminski, Artur; Soczawa, Michal] Pomeranian Med Univ, Dept Urol & Urol Oncol, Szczecin, Poland.
   [van de Wetering, Thierry] Gdanski Uniwerytet Med, Zaklad Med Diagnostyki Lab Gdansku, Gdansk, Poland.
   [Trubicka, Joanna] Childrens Mem Hlth Inst, Dept Pathol, Warsaw, Poland.
RP Zlowocka-Perlowska, E (corresponding author), Pomeranian Med Univ, Dept Genet & Pathol, Int Hereditary Canc Ctr, Unii Lubelskiej 1, PL-71252 Szczecin, Poland.
EM elzunik@wp.pl
CR Adank MA, 2010, PEDIATR BLOOD CANCER, V55, P742, DOI 10.1002/pbc.22588
   Cybulski C, 2015, CLIN GENET, V88, P366, DOI 10.1111/cge.12524
   Cybulski C, 2015, LANCET ONCOL, V16, P638, DOI 10.1016/S1470-2045(15)70142-7
   Dansonka-Mieszkowska A, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-20
   Erkko H, 2007, NATURE, V446, P316, DOI 10.1038/nature05609
   Foulkes WD, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1828
   Gronwald Jacek, 2006, Hered Cancer Clin Pract, V4, P56, DOI 10.1186/1897-4287-4-1-56
   Hayashi K, 2019, AM J NEPHROL, V50, P81, DOI 10.1159/000501356
   Heeke AL, 2018, JCO PRECIS ONCOL, V2, P1, DOI 10.1200/PO.17.00286
   Hsieh P, 2008, MECH AGEING DEV, V129, P391, DOI 10.1016/j.mad.2008.02.012
   Iqbal J, 2012, BRIT J CANCER, V107, P2005, DOI 10.1038/bjc.2012.483
   Kanchi KL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4156
   Lener MR, 2016, INT J CANCER, V139, P601, DOI 10.1002/ijc.30116
   Lupo B, 2014, BBA-REV CANCER, V1846, P201, DOI 10.1016/j.bbcan.2014.07.004
   Majidinia M, 2017, DNA REPAIR, V54, P22, DOI 10.1016/j.dnarep.2017.03.009
   Mouw KW, 2017, CANCERS, V9, DOI 10.3390/cancers9040028
   Nepomuceno TC, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091886
   Norquist BM, 2016, JAMA ONCOL, V2, P482, DOI 10.1001/jamaoncol.2015.5495
   Polo SE, 2011, GENE DEV, V25, P409, DOI 10.1101/gad.2021311
   Reid S, 2007, NAT GENET, V39, P162, DOI 10.1038/ng1947
   Rimar KJ, 2017, CANCER-AM CANCER SOC, V123, P1912, DOI 10.1002/cncr.30631
   Warner EW, 2019, BJU INT, V123, P769, DOI 10.1111/bju.14576
   Xia B, 2007, NAT GENET, V39, P159, DOI 10.1038/ng1942
   Xia B, 2006, MOL CELL, V22, P719, DOI 10.1016/j.molcel.2006.05.022
   Yap KL, 2014, CLIN CANCER RES, V20, P6605, DOI 10.1158/1078-0432.CCR-14-0257
NR 25
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1731-2302
EI 1897-4287
J9 HERED CANCER CLIN PR
JI Hered. Cancer Clin. Pract.
PD DEC 8
PY 2021
VL 19
IS 1
AR 6
DI 10.1186/s13053-020-00161-y
PG 5
WC Oncology
SC Oncology
GA PQ0ZZ
UT WOS:000606280400001
PM 33419454
OA DOAJ Gold, Green Published
DA 2021-01-23
ER

PT J
AU Priedigkeit, N
   Ding, K
   Horne, W
   Kolls, JK
   Du, T
   Lucas, PC
   Blohmer, JU
   Denkert, C
   Machleidt, A
   Ingold-Heppner, B
   Oesterreich, S
   Lee, AV
AF Priedigkeit, Nolan
   Ding, Kai
   Horne, William
   Kolls, Jay K.
   Du, Tian
   Lucas, Peter C.
   Blohmer, Jens-Uwe
   Denkert, Carsten
   Machleidt, Anna
   Ingold-Heppner, Barbara
   Oesterreich, Steffi
   Lee, Adrian V.
TI Acquired mutations and transcriptional remodeling in long-term
   estrogen-deprived locoregional breast cancer recurrences
SO BREAST CANCER RESEARCH
LA English
DT Article
DE Breast cancer; Estrogen receptor; Locoregional recurrence; Endocrine
   therapy; Therapy resistance; RNA-seq; DNA-seq; Copy number alterations;
   FFPE; Tumor profiling; Exome capture; Targeted sequencing; Cancer
   genomics; ESR1; NTRK; ARID1A
ID ENDOCRINE RESISTANCE; ESR1 MUTATIONS; BIOCONDUCTOR PACKAGE;
   AROMATASE-INHIBITOR; SOMATIC MUTATION; GENE ARID1A; RECEPTOR;
   EXPRESSION; TAMOXIFEN; CELLS
AB Background: Endocrine therapy resistance is a hallmark of advanced estrogen receptor (ER)-positive breast cancer. In this study, we aimed to determine acquired genomic changes in endocrine-resistant disease.
   Methods: We performed DNA/RNA hybrid-capture sequencing on 12 locoregional recurrences after long-term estrogen deprivation and identified acquired genomic changes versus each tumor's matched primary.
   Results: Despite being up to 7 years removed from the primary lesion, most recurrences harbored similar intrinsic transcriptional and copy number profiles. Only two genes, AKAP9 and KMT2C, were found to have single nucleotide variant (SNV) enrichments in more than one recurrence. Enriched mutations in single cases included SNVs within transcriptional regulators such as ARID1A, TP53, FOXO1, BRD1, NCOA1, and NCOR2 with one local recurrence gaining three PIK3CA mutations. In contrast to DNA-level changes, we discovered recurrent outlier mRNA expression alterations were common-including outlier gains in TP63 (n = 5 cases [42%]), NTRK3 (n = 5 [42%]), NTRK2 (n = 4 [33%]), PAX3 (n = 4 [33%]), FGFR4 (n = 3 [25%]), and TERT (n = 3 [25%]). Recurrent losses involved ESR1 (n = 5 [42%]), RELN (n = 5 [42%]), SFRP4 (n = 4 [33%]), and FOSB (n = 4 [33%]). ESR1-depleted recurrences harbored shared transcriptional remodeling events including upregulation of PROM1 and other basal cancer markers.
   Conclusions: Taken together, this study defines acquired genomic changes in long-term, estrogen-deprived disease; highlights the importance of longitudinal RNA profiling; and identifies a common ESR1-depleted endocrine-resistant breast cancer subtype with basal-like transcriptional reprogramming.
C1 [Priedigkeit, Nolan] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
   [Priedigkeit, Nolan; Ding, Kai; Du, Tian; Lucas, Peter C.; Oesterreich, Steffi; Lee, Adrian V.] UPMC Hillman Canc Ctr, Womens Canc Res Ctr, Pittsburgh, PA 15232 USA.
   [Ding, Kai; Oesterreich, Steffi; Lee, Adrian V.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15213 USA.
   [Ding, Kai; Oesterreich, Steffi; Lee, Adrian V.] Univ Pittsburgh, Med Ctr, Magee Womens Res Hosp, Magee Womens Res Inst, Pittsburgh, PA USA.
   [Horne, William; Kolls, Jay K.] UPMC Childrens Hosp Pittsburgh, Richard King Mellon Fdn Inst Pediat Res, Pittsburgh, PA USA.
   [Lucas, Peter C.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA.
   [Blohmer, Jens-Uwe; Machleidt, Anna] Charite, Inst Pathol, Berlin, Germany.
   [Blohmer, Jens-Uwe; Machleidt, Anna] Charite, Dept Gynecol, Berlin, Germany.
   [Denkert, Carsten] Philipps Univ Marburg, Inst Pathol, Marburg, Germany.
   [Denkert, Carsten] Univ Hosp Marburg UKGM, Marburg, Germany.
   [Ingold-Heppner, Barbara] DRK Kliniken Berlin, Inst Pathol, Berlin, Germany.
   [Lee, Adrian V.] Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA USA.
   [Lee, Adrian V.] Magee Womens Res Inst, 204 Craft Ave Room A412, Pittsburgh, PA 15213 USA.
RP Lee, AV (corresponding author), UPMC Hillman Canc Ctr, Womens Canc Res Ctr, Pittsburgh, PA 15232 USA.; Lee, AV (corresponding author), Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15213 USA.
EM leeav@upmc.edu
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [P30CA047904]; Susan G. Komen Scholar
   awardsSusan G. Komen Breast Cancer Foundation; Breast Cancer Research
   Foundation; Fashion Footwear Association of New York; Magee-Women's
   Research Institute and Foundation; Nicole Meloche Foundation; Penguins
   Foundation; Penguins Alumni Foundation; NIH/NIGMSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of General Medical Sciences (NIGMS)
   [2T32GM008424-21]; NIH/NCIUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [5F30CA203095]; University of Pittsburgh School of
   Medicine Dean's MSTP Postdoctoral Scholar Award
FX Research funding for this project was provided in part by NIH
   P30CA047904, Susan G. Komen Scholar awards (AVL and SO), Breast Cancer
   Research Foundation (AVL and SO), the Fashion Footwear Association of
   New York, Magee-Women's Research Institute and Foundation, Nicole
   Meloche Foundation, Penguins Foundation, Penguins Alumni Foundation,
   Mario Lemieux. NP was supported by a training grant from the NIH/NIGMS
   (2T32GM008424-21), an individual fellowship from the NIH/NCI
   (5F30CA203095), and University of Pittsburgh School of Medicine Dean's
   MSTP Postdoctoral Scholar Award.
CR Basudan A, 2019, MOL CANCER RES, V17, P457, DOI 10.1158/1541-7786.MCR-18-0946
   Bland JM, 2004, BRIT MED J, V328, P1073, DOI 10.1136/bmj.328.7447.1073
   Cejalvo JM, 2017, CANCER RES, V77, P2213, DOI 10.1158/0008-5472.CAN-16-2717
   Creighton CJ, 2006, CANCER RES, V66, P3903, DOI 10.1158/0008-5472.CAN-05-4363
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Davies C, 2011, LANCET, V378, P771, DOI 10.1016/S0140-6736(11)60993-8
   Davies C, 2013, LANCET, V381, P805, DOI 10.1016/S0140-6736(12)61963-1
   Du T, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-1041-8
   Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075
   Gao RL, 2016, NAT GENET, V48, P1119, DOI 10.1038/ng.3641
   Gervais R, 2005, ANN ONCOL, V16, P90, DOI 10.1093/annonc/mdi018
   Goss PE, 2016, NEW ENGL J MED, V375, P209, DOI 10.1056/NEJMoa1604700
   Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313
   Guan B, 2011, CANCER RES, V71, P6718, DOI 10.1158/0008-5472.CAN-11-1562
   Guang RJ, 2000, CANCER RES, V60, P749
   Gundem G, 2015, NATURE, V520, P353, DOI 10.1038/nature14347
   Gutierrez MC, 2005, J CLIN ONCOL, V23, P2469, DOI 10.1200/JCO.2005.01.172
   Hanker AB, 2017, CANCER DISCOV, V7, P575, DOI 10.1158/2159-8290.CD-16-1431
   Hartmaier RJ, 2018, ANN ONCOL, V29, P872, DOI 10.1093/annonc/mdy025
   Hugo W, 2015, CELL, V162, P1271, DOI 10.1016/j.cell.2015.07.061
   JACOBSON JA, 1995, NEW ENGL J MED, V332, P907, DOI 10.1056/NEJM199504063321402
   Jeselsohn R, 2018, CANCER CELL, V33, P173, DOI 10.1016/j.ccell.2018.01.004
   Jeselsohn R, 2015, NAT REV CLIN ONCOL, V12, P573, DOI 10.1038/nrclinonc.2015.117
   JOHNSTON SRD, 1995, CANCER RES, V55, P3331
   Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333
   Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111
   Kuukasjarvi T, 1996, J CLIN ONCOL, V14, P2584, DOI 10.1200/JCO.1996.14.9.2584
   Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r29
   Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057
   Levine KM, 2019, NPJ BREAST CANCER, V5, DOI 10.1038/s41523-019-0114-x
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Liu LX, 2015, ONCOTARGET, V6, P2466, DOI 10.18632/oncotarget.2967
   Loh YN, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-174
   Mackay A, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1732
   Manso L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155840
   McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110
   Miller CA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12498
   Miller WR, 2007, PHARMACOGENET GENOM, V17, P813, DOI 10.1097/FPC.0b013e32820b853a
   Nayar U, 2019, NAT GENET, V51, P207, DOI 10.1038/s41588-018-0287-5
   Nik-Zainal S, 2012, CELL, V149, DOI 10.1016/j.cell.2012.04.023
   Obenchain V, 2014, BIOINFORMATICS, V30, P2076, DOI 10.1093/bioinformatics/btu168
   Oh AS, 2001, MOL ENDOCRINOL, V15, P1344, DOI 10.1210/me.15.8.1344
   Olshen AB, 2004, BIOSTATISTICS, V5, P557, DOI 10.1093/biostatistics/kxh008
   Patro R, 2017, NAT METHODS, V14, P417, DOI 10.1038/nmeth.4197
   Pearson A, 2020, CLIN CANCER RES, V26, P608, DOI 10.1158/1078-0432.CCR-18-4044
   Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479
   Priedigkeit N, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.95703
   Priedigkeit N, 2017, JAMA ONCOL, V3, P666, DOI 10.1001/jamaoncol.2016.5630
   Razavi P, 2018, CANCER CELL, V34, P427, DOI 10.1016/j.ccell.2018.08.008
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Robinson DR, 2017, NATURE, V548, P297, DOI 10.1038/nature23306
   Robinson DR, 2013, NAT GENET, V45, P1446, DOI 10.1038/ng.2823
   Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754
   Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Saito Y, 2020, NATURE, V582, P95, DOI 10.1038/s41586-020-2175-2
   Sansone P, 2017, CANCER RES, V77, P1927, DOI 10.1158/0008-5472.CAN-16-2129
   Sansone P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10442
   Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166
   Siegel MB, 2018, J CLIN INVEST, V128, P1371, DOI 10.1172/JCI96153
   Sikora MJ, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0748-7
   Simigdala N, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0713-5
   Soneson Charlotte, 2015, F1000Res, V4, P1521, DOI 10.12688/f1000research.7563.2
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Talevich E, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004873
   Touat M, 2015, CLIN CANCER RES, V21, P2684, DOI 10.1158/1078-0432.CCR-14-2329
   Toy W, 2013, NAT GENET, V45, P1439, DOI 10.1038/ng.2822
   Turner N, 2010, CANCER RES, V70, P2085, DOI 10.1158/0008-5472.CAN-09-3746
   Vareslija D, 2019, JNCI-J NATL CANCER I, V111, P388, DOI 10.1093/jnci/djy110
   Vareslija D, 2016, CLIN CANCER RES, V22, P2765, DOI 10.1158/1078-0432.CCR-15-1583
   Veeck J, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-83
   Wahner-Roedler DL, 2011, CLIN BREAST CANCER, V11, P61, DOI 10.3816/CBC.2011.n.010
   Wang CH, 2017, CELL REP, V18, P2825, DOI 10.1016/j.celrep.2017.02.071
   Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603
   Wong SQ, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-23
   Xu GT, 2020, NAT GENET, V52, P198, DOI 10.1038/s41588-019-0554-0
   Zhang XY, 2012, CANCER EPIDEMIOL, V36, P288, DOI 10.1016/j.canep.2011.07.006
   Zheng ZY, 2020, CANCER CELL, V37, P387, DOI 10.1016/j.ccell.2020.02.003
   Zundelevich A, 2020, BREAST CANCER RES, V22, DOI 10.1186/s13058-020-1246-5
NR 79
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-5411
EI 1465-542X
J9 BREAST CANCER RES
JI Breast Cancer Res.
PD DEC 6
PY 2021
VL 23
IS 1
AR 1
DI 10.1186/s13058-020-01379-3
PG 14
WC Oncology
SC Oncology
GA PQ4PK
UT WOS:000606527200001
PM 33407744
OA DOAJ Gold, Green Published
DA 2021-01-23
ER

PT J
AU Wang, JY
   Ma, G
   Ge, H
   Han, X
   Mao, XR
   Wang, XY
   Veeramootoo, JS
   Xia, TS
   Liu, XA
   Wang, S
AF Wang, Jingyi
   Ma, Ge
   Ge, Han
   Han, Xu
   Mao, Xinrui
   Wang, Xinyang
   Veeramootoo, Jordee Selvamanee
   Xia, Tiansong
   Liu, Xiaoan
   Wang, Shui
TI Circulating tRNA-derived small RNAs (tsRNAs) signature for the diagnosis
   and prognosis of breast cancer
SO NPJ BREAST CANCER
LA English
DT Article
AB Liquid biopsy is noninvasive and convenient to detect cancer-derived materials in blood or other body fluids. The aim of this study was to identify tRNA-derived small RNAs (tsRNAs) in plasma that could distinguish patients with breast cancer (BC) from healthy controls. Basing on high-throughput sequencing, 15 significantly upregulated tsRNAs were selected and assessed in cell supernatants and cell lines. 6 tsRNAs were identified and verified in a large cohort of 120 patients with BC and 112 healthy controls. tRF-Arg-CCT-017, tRF-Gly-CCC-001, and tiRNA-Phe-GAA-003 could serve as novel diagnostic biomarkers. Meanwhile, tRF-Arg-CCT-017 and tiRNA-Phe-GAA-003 could also act as prognostic biomarkers. Target genes of these tsRNAs were related to the development of cancers. These results suggested that specific tsRNAs in plasma might serve as diagnostic and prognostic biomarkers of BC.
C1 [Wang, Jingyi; Ma, Ge; Ge, Han; Han, Xu; Mao, Xinrui; Wang, Xinyang; Veeramootoo, Jordee Selvamanee; Xia, Tiansong; Liu, Xiaoan; Wang, Shui] Nanjing Med Univ, Dept Breast Surg, Affiliated Hosp 1, 300 Guangzhou Rd, Nanjing 210029, Peoples R China.
   [Wang, Jingyi; Ma, Ge; Xia, Tiansong; Liu, Xiaoan; Wang, Shui] Nanjing Med Univ, Jiangsu Collaborat Innovat Ctr Canc Personalized, Sch Publ Hlth, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing 211166, Peoples R China.
RP Xia, TS; Liu, XA; Wang, S (corresponding author), Nanjing Med Univ, Dept Breast Surg, Affiliated Hosp 1, 300 Guangzhou Rd, Nanjing 210029, Peoples R China.; Xia, TS; Liu, XA; Wang, S (corresponding author), Nanjing Med Univ, Jiangsu Collaborat Innovat Ctr Canc Personalized, Sch Publ Hlth, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing 211166, Peoples R China.
EM xiatsswms@163.com; liuxiaoan@126.com; ws0801@hotmail.com
FU Natural Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [81572607, 81572602]; Natural Science Foundation of
   Jiangsu ProvinceNatural Science Foundation of Jiangsu Province
   [BK20171506]; Postgraduate Research & Practice Innovation Program of
   Jiangsu Province [KYCX19_1158]
FX The authors wish to thank all participants and family members for
   participating in this study. This study was funded by the Natural
   Science Foundation of China (81572607 and 81572602), the Natural Science
   Foundation of Jiangsu Province (BK20171506) and Postgraduate Research &
   Practice Innovation Program of Jiangsu Province (KYCX19_1158).
CR Adeli E, 2020, IEEE T PATTERN ANAL, V42, P1713, DOI 10.1109/TPAMI.2019.2901688
   [Anonymous], 2020, GENE EXPRESSION OMNI
   Balatti V, 2017, ADV CANCER RES, V135, P173, DOI 10.1016/bs.acr.2017.06.007
   Balatti V, 2017, P NATL ACAD SCI USA, V114, P8071, DOI 10.1073/pnas.1706908114
   DeSantis CE, 2019, CA-CANCER J CLIN, V69, P438, DOI 10.3322/caac.21583
   Giege R, 2008, NAT STRUCT MOL BIOL, V15, P1007, DOI 10.1038/nsmb.1498
   Goodarzi H, 2015, CELL, V161, P790, DOI 10.1016/j.cell.2015.02.053
   Guzzi N, 2018, CELL, V173, P1204, DOI 10.1016/j.cell.2018.03.008
   Kim HK, 2017, NATURE, V552, P57, DOI 10.1038/nature25005
   Kumar P, 2016, TRENDS BIOCHEM SCI, V41, P679, DOI 10.1016/j.tibs.2016.05.004
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Mo DP, 2019, CANCER LETT, V457, P60, DOI 10.1016/j.canlet.2019.05.007
   Pekarsky Y, 2016, P NATL ACAD SCI USA, V113, P5071, DOI 10.1073/pnas.1604266113
   Selitsky SR, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0800-0
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Timmerman D, 2005, J CLIN ONCOL, V23, P8794, DOI 10.1200/JCO.2005.01.7632
   Wang J, 2020, FIGSHARE, DOI [10.6084/m9.figshare.12961883, DOI 10.6084/M9.FIGSHARE.12961883]
   Zhao CM, 2018, J UROLOGY, V199, P378, DOI 10.1016/j.juro.2017.07.082
NR 18
TC 0
Z9 0
U1 0
U2 0
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2374-4677
J9 NPJ BREAST CANCER
JI npj Breast Cancer
PD DEC 5
PY 2021
VL 7
IS 1
AR 4
DI 10.1038/s41523-020-00211-7
PG 5
WC Oncology
SC Oncology
GA PO5IR
UT WOS:000605203200001
PM 33402674
OA DOAJ Gold
DA 2021-01-23
ER

PT J
AU Shimazaki, A
   Hashimoto, T
   Kai, M
   Nakayama, T
   Yamada, M
   Zaguirre, K
   Tokuda, K
   Kubo, M
   Yamaura, K
   Nakamura, M
AF Shimazaki, Akiko
   Hashimoto, Takuma
   Kai, Masaya
   Nakayama, Tetsuzo
   Yamada, Mai
   Zaguirre, Karen
   Tokuda, Kentaro
   Kubo, Makoto
   Yamaura, Ken
   Nakamura, Masafumi
TI Surgical treatment for breast cancer in a patient with erythropoietic
   protoporphyria and photosensitivity: a case report
SO SURGICAL CASE REPORTS
LA English
DT Article
DE Erythropoietic protoporphyria (EPP); Photosensitivity; Breast cancer
   surgery
ID LIVER-TRANSPLANTATION; PORPHYRIAS; SURGERY; FAILURE
AB Background Erythropoietic protoporphyria (EPP) is a rare disorder of heme synthesis. Patients with EPP mainly show symptoms of photosensitivity, but approximately 20% of EPPs are associated with the liver-related complications. We report a case of breast cancer in a 48-year-old female patient with EPP in whom meticulous perioperative management was required in order to avoid complications resulting from this disease. Case presentation The patient was diagnosed with EPP at the age of 33 and had a rich family history of the disease. For right breast cancer initially considered as TisN0M0 (Stage 0), the right mastectomy and sentinel lymph node biopsy were performed, while the final stage was pT1bN0M0, pStage I. In the perioperative period, we limited the drug use and monitored light wavelength measurements. Besides, we covered surgical lights, headlights, and laryngoscope's light with a special polyimide film that filtered the wavelength of light causing dermal photosensitivity. After the surgery, any emerging complications were closely monitored. Conclusions The surgery, internal medicine, anesthesiology, and operation departments undertook all possible measures through close cooperation to ensure a safe surgery for the patient with a rare condition.
C1 [Shimazaki, Akiko; Kai, Masaya; Yamada, Mai; Zaguirre, Karen; Kubo, Makoto; Nakamura, Masafumi] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Oncol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.
   [Hashimoto, Takuma; Yamaura, Ken] Kyushu Univ, Grad Sch Med Sci, Dept Anesthesiol & Crit Care Med, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.
   [Nakayama, Tetsuzo] Kyushu Univ Hosp, Higashi Ku, Operating Room,3-1-1 Maidashi, Fukuoka 8128582, Japan.
   [Tokuda, Kentaro] Kyushu Univ Hosp, Emergency & Crit Care Ctr, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.
RP Kubo, M (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Surg & Oncol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.
EM mkubo@tumor.med.kyushu-u.ac.jp
CR Akinci E, 2005, J CARDIAC SURG, V20, P267, DOI 10.1111/j.1540-8191.2005.200438.x
   Asokumar B, 1999, PAEDIATR ANAESTH, V9, P356, DOI 10.1046/j.1460-9592.1999.00338.x
   Balwani M, 2012, BLOOD, V120, P4496, DOI 10.1182/blood-2012-05-423186
   Bissell DM, 2017, NEW ENGL J MED, V377, P862, DOI 10.1056/NEJMra1608634
   Hanaki T, 2020, TRANSPL P, V52, P625, DOI 10.1016/j.transproceed.2019.12.004
   HERBERT A, 1991, GASTROENTEROLOGY, V100, P1753, DOI 10.1016/0016-5085(91)90680-J
   Kondo M, 2004, INT J HEMATOL, V79, P448, DOI 10.1532/IJH97.03127
   Kubo M, 2019, BREAST CANCER RES TR, V178, P647, DOI 10.1007/s10549-019-05413-7
   Lecha M, 2009, ORPHANET J RARE DIS, V4, DOI 10.1186/1750-1172-4-19
   MAGNUS IA, 1961, LANCET, V2, P448
   McGuire BM, 2005, LIVER TRANSPLANT, V11, P1590, DOI 10.1002/lt.20620
   Pagano MB, 2012, J CLIN APHERESIS, V27, P336, DOI 10.1002/jca.21249
   Park PJ, 2012, CLIN MOL HEPATOL, V18, P411, DOI 10.3350/cmh.2012.18.4.411
   Roe T, 2010, J SURG CASE REP, DOI 10.1093/jscr/2010.9.3
   Seth AK, 2007, LIVER TRANSPLANT, V13, P1219, DOI 10.1002/lt.21261
   Stolzel U, 2019, GASTROENTEROLOGY, V157, P365, DOI 10.1053/j.gastro.2019.04.050
   Wahlin S, 2008, LIVER TRANSPLANT, V14, P1340, DOI 10.1002/lt.21527
NR 17
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2198-7793
J9 SURG CASE REP
JI SURG. CASE REP.
PD DEC 5
PY 2021
VL 7
IS 1
AR 1
DI 10.1186/s40792-020-01068-5
PG 6
WC Surgery
SC Surgery
GA PO5IL
UT WOS:000605202600001
PM 33400006
OA DOAJ Gold
DA 2021-01-23
ER

PT J
AU Lao-Gonzalez, T
   Bueno-Soler, A
   Duran-Hernandez, A
   Sosa-Aguiar, K
   Hinojosa-Puerta, LE
   Hernandez-Garcia, T
   de la Luz-hernandez, KR
   Palacios-Oliva, J
   Boggiano-Ayo, T
AF Lao-Gonzalez, Thailin
   Bueno-Soler, Alexi
   Duran-Hernandez, Arnelys
   Sosa-Aguiar, Katya
   Hinojosa-Puerta, Luis Eduardo
   Hernandez-Garcia, Tays
   de la Luz-hernandez, Kathya Rashida
   Palacios-Oliva, Julio
   Boggiano-Ayo, Tammy
TI Screening and selection strategy for the establishment of biosimilar to
   trastuzumab-expressing CHO-K1 cell lines
SO AMB EXPRESS
LA English
DT Article
DE Biosimilar; Trastuzumab; CHO-K1 cells; Lentivirus; Intracellular
   staining; Flow cytometry
ID RECOMBINANT PROTEIN-PRODUCTION; MONOCLONAL-ANTIBODY; GLYCOSYLATION;
   PRODUCTIVITY; HEAVY; HERCEPTIN(R); TRANSFECTION; EFFICIENT; HYBRIDOMA;
   VECTORS
AB The high prices of biopharmaceuticals or biologics used in the treatment of many diseases limit the access of patients to these novel therapies. One example is the monoclonal antibody trastuzumab, successfully used for breast cancer treatment. An economic alternative is the generation of biosimilars to these expensive biopharmaceuticals. Since antibody therapies may require large doses over a long period of time, robust platforms and strategies for cell line development are essential for the generation of recombinant cell lines with higher levels of expression. Here, we obtained trastuzumab-expressing CHO-K1 cells through a screening and selection strategy that combined the use of host cells pre-adapted to protein-free media and suspension culture and lentiviral vectors. The results demonstrated that the early screening strategy obtained recombinant CHO-K1 cell populations with higher enrichment of IgG-expressing cells. Moreover, the measurement of intracellular heavy chain polypeptide by flow cytometry was a useful metric to characterize the homogeneity of cell population, and our results suggest this could be used to predict the expression levels of monoclonal antibodies in early stages of cell line development. Additionally, we propose an approach using 25 cm(2) T-flasks in suspension and shaking culture conditions as a screening tool to identify high producing cell lines. Finally, trastuzumab-expressing CHO-K1 clones were generated and characterized by batch culture, and preliminary results related to HER2-recognition capacity were successful. Further optimization of elements such as gene optimization, vector selection, type of amplification/selection system, cell culture media composition, in combination with this strategy will allow obtaining high producing clones.
C1 [Lao-Gonzalez, Thailin; Bueno-Soler, Alexi; Hernandez-Garcia, Tays; de la Luz-hernandez, Kathya Rashida; Palacios-Oliva, Julio; Boggiano-Ayo, Tammy] Ctr Mol Immunol, Proc Dev Direct, Havana 11600, Cuba.
   [Lao-Gonzalez, Thailin] Ctr Genet Engn & Biotechnol, Anim Biotechnol Div, Havana 10600, Cuba.
   [Duran-Hernandez, Arnelys] Univ Havana, Fac Biol, Havana, Cuba.
   [Sosa-Aguiar, Katya] Ctr Mol Immunol, Immunotherapy Direct, Havana 11600, Cuba.
   [Hinojosa-Puerta, Luis Eduardo] CIMAB SA, Havana 11600, Cuba.
RP Lao-Gonzalez, T (corresponding author), Ctr Mol Immunol, Proc Dev Direct, Havana 11600, Cuba.; Lao-Gonzalez, T (corresponding author), Ctr Genet Engn & Biotechnol, Anim Biotechnol Div, Havana 10600, Cuba.
EM thailin.lao@cigb.edu.cu
CR Agrawal Vishal, 2012, Methods Mol Biol, V911, P287, DOI 10.1007/978-1-61779-968-6_18
   Bandaranayake AD, 2014, FEBS LETT, V588, P253, DOI 10.1016/j.febslet.2013.11.035
   BERGMAN LW, 1981, J BIOL CHEM, V256, P701
   Borth N, 1999, J BIOTECHNOL, V67, P57, DOI 10.1016/S0168-1656(98)00162-X
   Chusainow J, 2009, BIOTECHNOL BIOENG, V102, P1182, DOI 10.1002/bit.22158
   Curigliano G, 2016, CRIT REV ONCOL HEMAT, V104, P131, DOI 10.1016/j.critrevonc.2016.06.002
   Dillman RO, 1999, CANCER BIOTHER RADIO, V14, P5, DOI 10.1089/cbr.1999.14.5
   Dorai H, 2006, HYBRIDOMA, V25, P1, DOI 10.1089/hyb.2006.25.1
   Dorai H, 2012, BIOTECHNOL BIOENG, V109, P1016, DOI 10.1002/bit.24367
   Edmonds MCDLC, 2006, MOL BIOTECHNOL, V34, P179, DOI 10.1385/MB:34:2:179
   Edros RZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075935
   Gaillet B, 2010, BIOTECHNOL BIOENG, V106, P203, DOI 10.1002/bit.22698
   Genentech, 1998, HERC PRESCR
   Godecke N, 2018, METHODS MOL BIOL, V1850, P43, DOI 10.1007/978-1-4939-8730-6_4
   Hacker DL, 2016, CURR OPIN STRUC BIOL, V38, P129, DOI 10.1016/j.sbi.2016.06.005
   Heffner K, 2015, CELL ENG, V9, P591, DOI 10.1007/978-3-319-10320-4_19
   Ho SCL, 2013, J BIOTECHNOL, V165, P157, DOI 10.1016/j.jbiotec.2013.03.019
   Ho SCL, 2012, J BIOTECHNOL, V157, P130, DOI 10.1016/j.jbiotec.2011.09.023
   Hutterer KM, 2019, BIODRUGS, DOI [10.1080/19420862.2017.1305530, DOI 10.1080/19420862.2017.1305530]
   Jiang Z, 2006, BIOTECHNOL PROGR, V22, P313, DOI 10.1021/bp0501524
   Jostock T, 2011, CELL ENG, V7, P1, DOI 10.1007/978-94-007-1257-7_1
   Kim JY, 2012, APPL MICROBIOL BIOT, V93, P917, DOI 10.1007/s00253-011-3758-5
   Kim S, 2017, MABS-AUSTIN, V9, P704, DOI 10.1080/19420862.2017.1305530
   Kober L, 2013, BIOTECHNOL BIOENG, V110, P1164, DOI 10.1002/bit.24776
   Krebs LE, 2018, BIOTECHNOL PROGR, V34, P570, DOI 10.1002/btpr.2667
   Kuystermans D, 2015, CELL ENG, V9, P717, DOI 10.1007/978-3-319-10320-4_23
   Kuystermans D, 2015, CELL ENG, V9, P327, DOI 10.1007/978-3-319-10320-4_11
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lattenmayer C, 2007, J BIOTECHNOL, V128, P716, DOI 10.1016/j.jbiotec.2006.12.016
   Le Fourn V, 2014, METAB ENG, V21, P91, DOI 10.1016/j.ymben.2012.12.003
   Lee CJ, 2009, BIOTECHNOL BIOENG, V102, P1107, DOI 10.1002/bit.22126
   LEE GM, 1993, BIOTECHNOL TECH, V7, P271, DOI 10.1007/BF00150897
   Li F, 2010, MABS-AUSTIN, V2, P466, DOI 10.4161/mabs.2.5.12720
   McDonnell S, 2015, CELL ENG, V9, P65, DOI 10.1007/978-3-319-10320-4_3
   Mora A, 2018, BIOTECHNOL PROGR, V34, P175, DOI 10.1002/btpr.2584
   Mursi IFA, 2018, APPL RNA BIOSCIENCE, P131, DOI [10.1007/978-981-10-8372-3_9, DOI 10.1007/978-981-10-8372-3_9]
   Nelson KM, 2014, EXPERT OPIN THER PAT, V24, P1149, DOI 10.1517/13543776.2014.964683
   Noh SM, 2018, SCI REP, V8, P1, DOI [10.1038/s41598-017-17765-5, DOI 10.1038/S41598-017-17765-5]
   Oberbek A, 2011, BIOTECHNOL BIOENG, V108, P600, DOI 10.1002/bit.22968
   Paplomata E, 2018, EXPERT OPIN BIOL TH, V18, P335, DOI 10.1080/14712598.2018.1430761
   PARK SH, 1994, BIOTECHNOL BIOENG, V44, P361, DOI 10.1002/bit.260440314
   Pivot X, 2018, BRIT J CANCER, V119, P263, DOI 10.1038/s41416-018-0171-1
   Porter AJ, 2010, BIOTECHNOL PROGR, V26, P1455, DOI 10.1002/btpr.443
   Priola JJ, 2016, BIOTECHNOL J, V11, P853, DOI 10.1002/biot.201500579
   Roy G, 2017, J IMMUNOL METHODS, V451, P100, DOI 10.1016/j.jim.2017.08.012
   Schlatter S, 2005, BIOTECHNOL PROGR, V21, P122, DOI 10.1021/bp049780w
   Spearman M, 2015, CELL ENG, V9, P237, DOI 10.1007/978-3-319-10320-4_9
   Toledo JR, 2009, APPL BIOCHEM BIOTECH, V157, P538, DOI 10.1007/s12010-008-8381-2
   Wurm FM, 2016, BIOSIMILARS MONOCLON, P327, DOI [10.1002/9781118940648.ch11, DOI 10.1002/9781118940648.CH11]
NR 49
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2191-0855
J9 AMB EXPRESS
JI AMB Express
PD DEC 3
PY 2021
VL 11
IS 1
AR 1
DI 10.1186/s13568-020-01157-6
PG 17
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA PN1OI
UT WOS:000604255800001
PM 33389203
OA DOAJ Gold, Green Published
DA 2021-01-23
ER

PT J
AU Hashemi, M
   Haghgoo, Z
   Yazdian-Robati, R
   Shahgordi, S
   Salmasi, Z
   Abnous, K
AF Hashemi, Maryam
   Haghgoo, Zahra
   Yazdian-Robati, Rezvan
   Shahgordi, Sanaz
   Salmasi, Zahra
   Abnous, Khalil
TI Improved anticancer efficiency of Mitoxantrone by Curcumin loaded PLGA
   nanoparticles targeted with AS1411 aptamer
SO NANOMEDICINE JOURNAL
LA English
DT Article
DE AS1411 aptamer; Breast cancer; Curcumin; Mitoxantrone; Polymeric
   nanoparticles
ID CANCER-CELLS; IN-VITRO; DELIVERY-SYSTEM; DOXORUBICIN; APOPTOSIS;
   EPIRUBICIN; PACLITAXEL; THERAPY; DESIGN; BLOCK
AB Objective(s): Mitoxantrone (MTX) is one of the most commonly used chemotherapeutic agents for treatment of different cancers. However, prolonged treatment with MTX results in unwanted side effects and drug resistant cancer cells. Combination therapies and exploiting of targeted nanoparticles have the potential of improving the efficiency of drug treatment as well as reducing the side effects. Curcumin (CUR) is a biological molecules with anticancer property. In this study, we investigated whether targeted PLGA (Poly Lactic-co-Glycolic Acid)-CUR nanoparticles (NPs) can reinforce the effect of MTX on breast cancer cells.
   Materials and Methods: PLGA NPs containing CUR targeted with AS1411 aptamer were prepared by single emulsion evaporation method. Physicochemical properties of NPs were investigated. The cytotoxicity of non-targeted and targeted NPs along with MTX was evaluated on MCF7, 4T1 and L929 cell lines.
   Results: The results showed that PLGA-CUR NPs were synthetized with an average encapsulation efficiency of 66% with a mean size of 186 +/- 3.2 nm. The drug release of curcumin from these NPs within 72h was about 59% in neutral medium and 90% in acidic medium. Interestingly, the combined treatment with PLGA-CUR-Apt and MTX inhibited the cancer cell's proliferation significantly more than the non-targeted nanoparticles, CUR and MTX-treated group alone.
   Conclusion: These results suggest that targeted PLGA-CUR nanoparticles may consider as a potential therapeutic contender in improving the efficacy of MTX in Breast cancer therapy.
C1 [Hashemi, Maryam; Salmasi, Zahra] Mashhad Univ Med Sci, Pharmaceut Technol Inst, Nanotechnol Res Ctr, Mashhad, Razavi Khorasan, Iran.
   [Hashemi, Maryam] Mashhad Univ Med Sci, Dept Pharmaceut Biotechnol, Sch Pharm, Mashhad, Razavi Khorasan, Iran.
   [Haghgoo, Zahra] Mashhad Univ Med Sci, Sch Pharm, Mashhad, Razavi Khorasan, Iran.
   [Yazdian-Robati, Rezvan] Mazandaran Univ Med Sci, Fac Med, Mol & Cell Biol Res Ctr, Sari, Iran.
   [Shahgordi, Sanaz] Golestan Univ Med Sci, Sch Med, Dept Immunol, Gorgan, Golestan, Iran.
   [Abnous, Khalil] Mashhad Univ Med Sci, Sch Pharm, Dept Med Chem, Mashhad, Razavi Khorasan, Iran.
RP Salmasi, Z (corresponding author), Mashhad Univ Med Sci, Pharmaceut Technol Inst, Nanotechnol Res Ctr, Mashhad, Razavi Khorasan, Iran.; Abnous, K (corresponding author), Mashhad Univ Med Sci, Sch Pharm, Dept Med Chem, Mashhad, Razavi Khorasan, Iran.
EM salmasiz@mums.ac.ir; abnouskh@mums.ac.ir
FU Mashhad University of Medical Sciences [961941]
FX The authors are grateful for the financial support provided by the
   Mashhad University of Medical Sciences (numbers: 961941).
CR Abnous K, 2017, RSC ADV, V7, P15181, DOI 10.1039/c6ra28234b
   Abouzeid AH, 2013, J DRUG TARGET, V21, P994, DOI 10.3109/1061186X.2013.840639
   Ahmadpour S, 2019, LIFE SCI, V239, DOI 10.1016/j.lfs.2019.116870
   Ansari N, 2018, MICROCHIM ACTA, V185, DOI 10.1007/s00604-017-2550-3
   Aravind A, 2013, J MAGN MAGN MATER, V344, P116, DOI 10.1016/j.jmmm.2013.05.036
   Aravind A, 2012, BIOTECHNOL BIOENG, V109, P2920, DOI 10.1002/bit.24558
   Banerjee M, 2010, FEBS J, V277, P3437, DOI 10.1111/j.1742-4658.2010.07750.x
   Banerjee Saswati, 2017, Front Biosci (Elite Ed), V9, P235
   Bates PJ, 2017, BBA-GEN SUBJECTS, V1861, P1414, DOI 10.1016/j.bbagen.2016.12.015
   Bayat P, 2019, TALANTA, V194, P399, DOI 10.1016/j.talanta.2018.10.063
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   Cui Y, 2016, ACS APPL MATER INTER, V8, P32159, DOI 10.1021/acsami.6b10175
   Dhillon N, 2008, CLIN CANCER RES, V14, P4491, DOI 10.1158/1078-0432.CCR-08-0024
   DSouza S., 2014, IJAP, V2014
   Duan JH, 2012, INT J PHARMACEUT, V426, P193, DOI 10.1016/j.ijpharm.2012.01.020
   Ebrahimian M, 2017, APPL BIOCHEM BIOTECH, V183, P126, DOI 10.1007/s12010-017-2434-3
   Epelbaum R, 2010, NUTR CANCER, V62, P1137, DOI 10.1080/01635581.2010.513802
   Ghahestani ZH, 2017, ARTIF CELL NANOMED B, V45, P955, DOI 10.1080/21691401.2016.1198359
   Guo JW, 2011, BIOMATERIALS, V32, P8010, DOI 10.1016/j.biomaterials.2011.07.004
   Guorgui J, 2018, ARCH BIOCHEM BIOPHYS, V648, P12, DOI 10.1016/j.abb.2018.04.012
   Nguyen HT, 2018, ACTA BIOMATER, V68, P154, DOI 10.1016/j.actbio.2017.12.033
   Hashemi M, 2020, ARCH BIOCHEM BIOPHYS, V691, DOI 10.1016/j.abb.2020.108485
   Hashemi M, 2017, NANOMED J, V4, P1, DOI 10.22038/nmj.2017.8046
   Huang YF, 2009, CHEMBIOCHEM, V10, P862, DOI 10.1002/cbic.200800805
   Irving GRB, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0641-1
   Jin H, 2015, ONCOL REP, V34, P2782, DOI 10.3892/or.2015.4258
   Jung YJ, 2007, BBA-MOL CELL RES, V1773, P383, DOI 10.1016/j.bbamcr.2006.11.004
   Kardani A, 2020, J CELL PHYSIOL, V235, P6887, DOI 10.1002/jcp.29584
   Kunwar A, 2008, BBA-GEN SUBJECTS, V1780, P673, DOI 10.1016/j.bbagen.2007.11.016
   Kurosaki T, 2012, GENE, V491, P205, DOI 10.1016/j.gene.2011.09.021
   Ma Q, 2019, DRUG DES DEV THER, V13, P4021, DOI 10.2147/DDDT.S210949
   Mackenzie GG, 2008, INT J CANCER, V123, P56, DOI 10.1002/ijc.23477
   Mosafer J, 2017, MAT SCI ENG C-MATER, V72, P123, DOI 10.1016/j.msec.2016.11.053
   Mujokoro B, 2020, J PHARM INNOV, V15, P617, DOI 10.1007/s12247-019-09406-3
   Nagpal Monika, 2013, J Nat Sci Biol Med, V4, P3, DOI 10.4103/0976-9668.107253
   Patil P, 2012, RJPPD, V4, P77
   Rejhova A, 2018, EUR J MED CHEM, V144, P582, DOI 10.1016/j.ejmech.2017.12.039
   Sa G, 2008, CELL DIV, V3, DOI 10.1186/1747-1028-3-14
   Saleh T, 2019, INT J BIOL MACROMOL, V130, P109, DOI 10.1016/j.ijbiomac.2019.02.129
   Saravanakumar K, 2019, ARCH BIOCHEM BIOPHYS, V671, P143, DOI 10.1016/j.abb.2019.07.004
   Serova M, 2011, BRIT J CANCER, V104, P272, DOI 10.1038/sj.bjc.6606063
   Shahgordi S, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106525
   Shaikh J, 2009, EUR J PHARM SCI, V37, P223, DOI 10.1016/j.ejps.2009.02.019
   Shanmugam MK, 2015, MOLECULES, V20, P2728, DOI 10.3390/molecules20022728
   Shao ZM, 2002, INT J CANCER, V98, P234, DOI 10.1002/ijc.10183
   Sinha R, 2006, MOL CANCER THER, V5, P1909, DOI 10.1158/1535-7163.MCT-06-0141
   Song ZM, 2011, J COLLOID INTERF SCI, V354, P116, DOI 10.1016/j.jcis.2010.10.024
   Taghdisi SM, 2018, MOL PHARMACEUT, V15, P1972, DOI 10.1021/acs.molpharmaceut.8b00124
   Verderio P, 2013, BIOMACROMOLECULES, V14, P672, DOI 10.1021/bm3017324
   Xu GJ, 2016, INT J NANOMED, V11, DOI 10.2147/IJN.S103513
   Xu XB, 2014, GENE, V546, P226, DOI 10.1016/j.gene.2014.06.006
   Yazdian-Robati R, 2020, INT J BIOL MACROMOL, V155, P1420, DOI 10.1016/j.ijbiomac.2019.11.118
   Yazdian-Robati R, 2017, MICROCHIM ACTA, V184, P4029, DOI 10.1007/s00604-017-2436-4
   Yazdian-Robati R, 2016, PHARM RES-DORDR, V33, P2289, DOI 10.1007/s11095-016-1967-4
   Yoo HS, 2001, J CONTROL RELEASE, V70, P63, DOI 10.1016/S0168-3659(00)00340-0
   Yoo HS, 2000, J CONTROL RELEASE, V68, P419, DOI 10.1016/S0168-3659(00)00280-7
   Yu B, 2020, J DRUG DELIV SCI TEC, V57, DOI 10.1016/j.jddst.2020.101739
   Zhou L, 2015, INT J NANOMED, V10, P5205, DOI 10.2147/IJN.S84326
NR 58
TC 0
Z9 0
U1 0
U2 0
PU MASHHAD UNIV MED SCIENCES
PI MASHHAD
PA VICE-CHANCELLOR FOR RES CTR OFF IJBMS, DANESHGAH ST, PO BOX 9138813944 -
   445, MASHHAD, 00000, IRAN
SN 2322-3049
EI 2322-5904
J9 NANOMED J
JI Nanomed. J.
PD WIN
PY 2021
VL 8
IS 1
BP 21
EP 29
DI 10.22038/nmj.2021.08.03
PG 9
WC Nanoscience & Nanotechnology
SC Science & Technology - Other Topics
GA PN2TI
UT WOS:000604336800003
OA DOAJ Gold
DA 2021-01-23
ER

PT J
AU Mansouri, E
   Mesbahi, A
   Yazdani, P
AF Mansouri, Elham
   Mesbahi, Asghar
   Yazdani, Parivar
TI Analysis of physical dose enhancement in nano-scale for
   nanoparticle-based radiation therapy: a Cluster and endothelial cell
   model
SO NANOMEDICINE JOURNAL
LA English
DT Article
DE Dose Enhancement; Radiation Therapy; Radiosensitization; Nanoparticle;
   Nano-Cluster
ID BREAST-CANCER CELLS; GOLD NANOPARTICLES; MONTE-CARLO; SHIELDING
   PROPERTIES; AGENTS; MICRO; RADIOSENSITIZATION; BRACHYTHERAPY;
   RADIOTHERAPY; PARTICLES
AB Objective(s): One major difficulty of conventional radiotherapy is the lack of selectivity between the tumor and the organs at risk. In nanoparticle aided radiotherapy, heavy elements are present at higher concentrations in the tumor than normal tissues. This study aimed to model the characteristics of secondary electrons generated from the interaction of clusters comprised of five different nanoparticles including Gold, Gadolinium, Iridium, Bismuth, and Hafnium atoms with low energy x-rays (similar to brachytherapy sources in terms of energy) as a function of nanoparticle size and beam energy.
   Materials and Methods: To better evaluate the contributions of secondary electrons in energy deposition, and also to develop a framework in analyzing further measurements in the future, we attempted to enhance and promote existing mathematical models for energy deposition in endothelial cells by nanoparticle-enhanced radiotherapy. Also, the MCNPX Monte Carlo code was used to model the identical geometry and the dose enhancement factor was calculated for all types of simulated nano-clusters.
   Results: Our results showed that for our model consist of a nano-cluster and an endothelial cell the DEF significantly depends on the energy of photons and L- and K-edge binding energy of the atoms inside the nano-cluster. However, for Gd at the energy 60 keV, a higher dose enhancement factor was seen.
   Conclusion: It can be concluded that the mathematical model considers the DEF variation with photon energy and the effect of NP type is considered in DEF calculations. However, the MC method has indicated very high sensitivity to photon energy, and NP type compared to the mathematical method.
C1 [Mansouri, Elham] Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz, Iran.
   [Mesbahi, Asghar; Yazdani, Parivar] Tabriz Univ Med Sci, Mol Med Res Ctr, Tabriz, Iran.
   [Mesbahi, Asghar] Tabriz Univ Med Sci, Med Radiat Sci Res Team, Tabriz, Iran.
RP Mesbahi, A (corresponding author), Tabriz Univ Med Sci, Mol Med Res Ctr, Tabriz, Iran.; Mesbahi, A (corresponding author), Tabriz Univ Med Sci, Med Radiat Sci Res Team, Tabriz, Iran.
EM amesbahi2010@gmail.com
FU Drug Applied research center of Tabriz Univerity Of Medical Science
FX This project was supported by Drug Applied research center of Tabriz
   Univerity Of Medical Science as a part of the PhD thesis in medical
   physics. The authors would like to thank the molecular medicine research
   center and medical physics department of Tabriz Univerity Of Medical
   Science for providing the required computer hardware for MC simulation.
CR Afkham Y, 2020, RADIAT ONCOL, V15, DOI 10.1186/s13014-020-01551-1
   Badrigilan S, 2020, INT J NANOSCI, V19, DOI 10.1142/S0219581X18500436
   Badrigilan S, 2019, PHOTODIAGN PHOTODYN, V25, P504, DOI 10.1016/j.pdpdt.2018.10.021
   Bazak R, 2015, J CANCER RES CLIN, V141, P769, DOI 10.1007/s00432-014-1767-3
   Berbeco RI, 2011, INT J RADIAT ONCOL, V81, P270, DOI 10.1016/j.ijrobp.2010.10.022
   Butterworth KT, 2008, RADIAT RES, V170, P381, DOI 10.1667/RR1320.1
   Butterworth KT, 2012, NANOSCALE, V4, P4830, DOI 10.1039/c2nr31227a
   Chithrani DB, 2010, RADIAT RES, V173, P719, DOI 10.1667/RR1984.1
   Cooper DR, 2014, FRONT CHEM, V2, DOI 10.3389/fchem.2014.00086
   Ghavami SM, 2016, NUCL TECHNOL RADIAT, V31, P89, DOI 10.2298/NTRP1601089G
   Hainfeld JF, 2008, J PHARM PHARMACOL, V60, P977, DOI 10.1211/jpp.60.8.0005
   Hildenbrand G, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190183
   Hossain M, 2012, J PHYS CHEM C, V116, P23047, DOI 10.1021/jp306543q
   Howell RW, 2008, INT J RADIAT BIOL, V84, P959, DOI 10.1080/09553000802395527
   Islamian JP, 2017, BREAST, V33, P97, DOI 10.1016/j.breast.2017.03.009
   Jain S, 2012, BRIT J RADIOL, V85, P101, DOI 10.1259/bjr/59448833
   Jangjoo AG, 2019, POL J MED PHYS ENG, V25, P87, DOI 10.2478/pjmpe-2019-0012
   Khodadadi A, 2019, APPL RADIAT ISOTOPES, V145, P39, DOI 10.1016/j.apradiso.2018.11.013
   Kobayashi K, 2010, MUTAT RES-REV MUTAT, V704, P123, DOI 10.1016/j.mrrev.2010.01.002
   Kong T, 2008, SMALL, V4, P1537, DOI 10.1002/smll.200700794
   Lee C, 2012, J PHYS CHEM C, V116, P11292, DOI 10.1021/jp210301q
   Leung MKK, 2011, MED PHYS, V38, P624, DOI 10.1118/1.3539623
   Malekzadeh R, 2019, RADIOL PHYS TECHNOL, V12, P325, DOI 10.1007/s12194-019-00529-3
   Mansouri E, 2020, ADSORPTION, V26, P835, DOI 10.1007/s10450-020-00217-4
   McMahon SJ, 2011, SCI REP-UK, V1, DOI 10.1038/srep00018
   Mesbahi A, 2019, POL J MED PHYS ENG, V25, P211, DOI 10.2478/pjmpe-2019-0028
   Mesbahi A, 2018, APPL RADIAT ISOTOPES, V136, P27, DOI 10.1016/j.apradiso.2018.02.004
   Mesbahi A, 2017, POL J MED PHYS ENG, V23, P9, DOI 10.1515/pjmpe-2017-0003
   Mesbahi A, 2013, BIOIMPACTS, V3, P29, DOI 10.5681/bi.2013.002
   Mesbahi A, 2010, REP PRACT ONCOL RADI, V15, P176, DOI 10.1016/j.rpor.2010.09.001
   Mortezazadeh T, 2020, J DRUG TARGET, V28, P533, DOI 10.1080/1061186X.2019.1703188
   Ngwa W, 2010, PHYS MED BIOL, V55, P6533, DOI 10.1088/0031-9155/55/21/013
   Paro AD, 2016, INT J NANOMED, V11, P4735, DOI 10.2147/IJN.S114025
   Peukert D, 2018, PHYS MEDICA, V47, P121, DOI 10.1016/j.ejmp.2018.03.004
   Porcel E, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/8/085103
   Retif P, 2016, INT J NANOSCI, V11
   Roeske JC, 2007, TECHNOL CANCER RES T, V6, P395, DOI 10.1177/153303460700600504
   Sadeghian M, 2020, POL J MED PHYS ENG, V26, P21, DOI 10.2478/pjmpe-2020-0003
   Vallieres S., 2016, DOSE ENHANCEMENT NAN
   Verdipoor K, 2020, IJMP, V17, P205
   Verdipoor K, 2018, RADIAT PHYS CHEM, V147, P85, DOI 10.1016/j.radphyschem.2018.02.017
   Villagomez-Bernabe B, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44482-y
   Yazdani P, 2019, ARTIF CELL NANOMED B, V47, P436, DOI 10.1080/21691401.2018.1559182
   Zareei L, 2019, J Biomed Phys Eng, V9, P211
   Zheng Y, 2009, RADIAT RES, V172, P114, DOI 10.1667/RR1689.1
   Zygmanski P, 2016, BRIT J RADIOL, V89, DOI 10.1259/bjr.20150200
NR 46
TC 0
Z9 0
U1 0
U2 0
PU MASHHAD UNIV MED SCIENCES
PI MASHHAD
PA VICE-CHANCELLOR FOR RES CTR OFF IJBMS, DANESHGAH ST, PO BOX 9138813944 -
   445, MASHHAD, 00000, IRAN
SN 2322-3049
EI 2322-5904
J9 NANOMED J
JI Nanomed. J.
PD WIN
PY 2021
VL 8
IS 1
BP 30
EP 41
DI 10.22038/nmj.2021.08.04
PG 12
WC Nanoscience & Nanotechnology
SC Science & Technology - Other Topics
GA PN2TI
UT WOS:000604336800004
OA DOAJ Gold
DA 2021-01-23
ER

PT J
AU Shamasi, Z
   Es-haghi, A
   Yazdi, MET
   Amiri, MS
   Homayouni-Tabrizi, M
AF Shamasi, Zahra
   Es-haghi, Ali
   Yazdi, Mohammad Ehsan Taghavizadeh
   Amiri, Mohammad Sadegh
   Homayouni-Tabrizi, Masoud
TI Role of Rubia tinctorum in the synthesis of zinc oxide nanoparticles and
   apoptosis induction in breast cancer cell line
SO NANOMEDICINE JOURNAL
LA English
DT Article
DE Apoptosis; Breast cancer; Green Synthesis; Rubia tinctorum; zinc oxide
   nanoparticles
ID SILVER NANOPARTICLES; ZNO NANOPARTICLES; ANTIBACTERIAL; CYTOTOXICITY;
   CHEMISTRY; DELIVERY; SENSOR
AB Objective(s): Nowadays, nanotechnology has offered great success in resolving concerns in cancer therapy and created a new interdisciplinary field of study incorporating various sciences, such as biology, chemistry and medicine. Apoptosis is a conserved and controlled strategy in regulating cellular growth and proliferation, as well as preserving development and general homeostasis of the body. Zinc oxide nanoparticles (ZnO-NPs) are the most important and widely used nanoparticles. This study aimed to evaluate the apoptosis-inducing properties of the synthesized ZnO-NPs by aqueous extract of Rubia tinctorum against the MCF7 breast cancer cell line.
   Materials and Methods: Zinc oxide nanoparticles were synthesized using rubia tinctorum extract and characterized by some methods including dynamic light scattering (DLS), field emission scanning electron microscopy (FESEM) and x-ray diffraction analysis (XRD). Apoptosis was measured by the Hoechst and Acridine-Orange/Propodium Iodide staining, as well as flow cytometry.
   Results: The results of this study showed that the particle size of biosynthesized ZnO-NPs using R.tinctorum extract was about 40 nm and had a spherical morphology. The obtain results of the Hoechst and Acridine-Orange/Propodium Iodide staining, as well as flow cytometry showed that biosynthesized ZnO-NPs effectively and dose-dependently induced apoptosis in the MCF7 breast cancer cells.
   Conclusion: Therefore, the biosynthesized ZnO-NPs by watery extract of R. tinctorum can be used in the treatment of many diseases, including cancers.
C1 [Shamasi, Zahra; Es-haghi, Ali; Homayouni-Tabrizi, Masoud] Islamic Azad Univ, Dept Biol, Mashhad Branch, Mashhad, Razavi Khorasan, Iran.
   [Yazdi, Mohammad Ehsan Taghavizadeh] Mashhad Univ Med Sci, Med Toxicol Res Ctr, Sch Med, Mashhad, Razavi Khorasan, Iran.
   [Amiri, Mohammad Sadegh] Payame Noor Univ, Dept Biol, Tehran, Iran.
RP Es-haghi, A (corresponding author), Islamic Azad Univ, Dept Biol, Mashhad Branch, Mashhad, Razavi Khorasan, Iran.
EM ashaghi@gmail.com
CR Ahmad H, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10030425
   Alarifi S, 2013, INT J NANOMED, V8, P983, DOI 10.2147/IJN.S42028
   Alavi-Tabari SAR, 2018, J ELECTROANAL CHEM, V811, P84, DOI 10.1016/j.jelechem.2018.01.034
   Albanese A, 2012, ANNU REV BIOMED ENG, V14, P1, DOI [10.1146/annurev-bioeng-071811-150124, 10.1146/annurev.bioeng-071811-150124]
   Ani IJ, 2018, J CLEAN PROD, V205, P930, DOI 10.1016/j.jclepro.2018.08.189
   BANK HL, 1988, IN VITRO CELL DEV B, V24, P266
   Behl C, 2000, J NEURAL TRANSM, V107, P1325, DOI 10.1007/s007020070021
   Burz C, 2009, ACTA ONCOL, V48, P811, DOI 10.1080/02841860902974175
   Chauhan AK, 2020, CHEMOSPHERE, V247, DOI 10.1016/j.chemosphere.2019.125803
   Crowley LC, 2016, COLD SPRING HARB PRO, V2016
   Darroudi M, 2020, 21 CENTURY NANOSCIEN, P1
   De Berardis B, 2010, TOXICOL APPL PHARM, V246, P116, DOI 10.1016/j.taap.2010.04.012
   Deng XY, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/11/115101
   Dhandapani KV, 2020, BIOCATAL AGR BIOTECH, V24, DOI 10.1016/j.bcab.2020.101517
   DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G
   Einafshar E, 2018, NANOMED J, V5, P210, DOI 10.22038/nmj.2018.05.00004
   Es-haghi A, 2019, AVICENNA J MED BIOCH, V7, P16, DOI [10.34172/ajmb.2019.04, DOI 10.34172/AJMB.2019.04]
   Fahimmunisha BA, 2020, J DRUG DELIV SCI TEC, V55, DOI 10.1016/j.jddst.2019.101465
   Favaloro B, 2012, AGING-US, V4, P330, DOI 10.18632/aging.100459
   Goldar Samira, 2015, Asian Pac J Cancer Prev, V16, P2129
   Guo DD, 2008, J PHOTOCH PHOTOBIO B, V93, P119, DOI 10.1016/j.jphotobiol.2008.07.009
   Hamidi A, 2019, RES CHEM INTERMEDIAT, V45, P2915, DOI 10.1007/s11164-019-03770-y
   Hipfner DR, 2004, NAT REV MOL CELL BIO, V5, P805, DOI 10.1038/nrm1491
   Javadi F, 2019, MATER RES EXPRESS, V6, DOI 10.1088/2053-1591/ab08ff
   Krol A, 2017, ADV COLLOID INTERFAC, V249, P37, DOI 10.1016/j.cis.2017.07.033
   Liu XS, 2020, COLLOID SURFACE A, V584, DOI 10.1016/j.colsurfa.2019.124011
   Marsden VS, 2003, ANNU REV IMMUNOL, V21, P71, DOI 10.1146/annurev.immunol.21.120601.141029
   Modarres M, 2018, CYTOTECHNOLOGY, V70, P741, DOI 10.1007/s10616-017-0178-0
   Mohamadian F, 2018, NANOMED J, V5, P217, DOI 10.22038/nmj.2018.05.00005
   Nezhad SA, 2020, APPL ORGANOMET CHEM, V34, DOI 10.1002/aoc.5314
   Noohpisheh Z, 2020, SPECTROCHIM ACTA A, V240, DOI 10.1016/j.saa.2020.118595
   Oancea Marcela, 2006, V129, P279
   Plati J, 2011, INTEGR BIOL-UK, V3, P279, DOI 10.1039/c0ib00144a
   Rahnama M, 2018, MOL PLANT MICROBE IN, V31, P591, DOI 10.1094/MPMI-11-17-0286-R
   Rai M, 2013, IET NANOBIOTECHNOL, V7, P117, DOI 10.1049/iet-nbt.2012.0031
   Saad AM, 2020, J ENVIRON MANAGE, V258, DOI 10.1016/j.jenvman.2019.110043
   Selim YA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60541-1
   Sharifan H, 2020, ECOTOX ENVIRON SAFE, V191, DOI 10.1016/j.ecoenv.2020.110177
   Shetti NP, 2019, BIOSENS BIOELECTRON, V141, DOI 10.1016/j.bios.2019.111417
   Sun J, 2018, J CHEM RES, P184, DOI 10.3184/174751918X15232701502261
   Wang CX, 2015, PROCESS SAF ENVIRON, V93, P265, DOI 10.1016/j.psep.2014.05.007
   Wang C, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/328707
   Wilczewska AZ, 2012, PHARMACOL REP, V64, P1020, DOI 10.1016/S1734-1140(12)70901-5
   Yao J, 2014, CHEM REV, V114, P6130, DOI 10.1021/cr200359p
   Yazdi M E T, 2018, INT J BASIC SCI MED, V3, P99, DOI DOI 10.15171/ijbsm.2018.18
   Yazdi MET, 2019, MATER TECHNOL, V34, P490, DOI 10.1080/10667857.2019.1583408
   Yazdi MET, 2019, B MATER SCI, V42, DOI 10.1007/s12034-019-1855-8
   Yazdi MET, 2019, IET NANOBIOTECHNOL, V13, P189, DOI 10.1049/iet-nbt.2018.5215
   Yazdi MET, 2018, RES CHEM INTERMEDIAT, V44, P1325, DOI 10.1007/s11164-017-3169-z
   Yazdi T, 2020, STUDIES MED SCI, V31, P75
   Zabihi E, 2019, INT J BIOL MACROMOL, V131, P107, DOI 10.1016/j.ijbiomac.2019.01.224
   Zarei M, 2020, NUTR CANCER, DOI 10.1080/01635581.2020.1801780
   Zhu L, 2017, SENSOR ACTUAT A-PHYS, V267, P242, DOI 10.1016/j.sna.2017.10.021
NR 53
TC 0
Z9 0
U1 0
U2 0
PU MASHHAD UNIV MED SCIENCES
PI MASHHAD
PA VICE-CHANCELLOR FOR RES CTR OFF IJBMS, DANESHGAH ST, PO BOX 9138813944 -
   445, MASHHAD, 00000, IRAN
SN 2322-3049
EI 2322-5904
J9 NANOMED J
JI Nanomed. J.
PD WIN
PY 2021
VL 8
IS 1
BP 65
EP 72
DI 10.22038/nmj.2021.08.07
PG 8
WC Nanoscience & Nanotechnology
SC Science & Technology - Other Topics
GA PN2TI
UT WOS:000604336800007
OA DOAJ Gold
DA 2021-01-23
ER

PT J
AU Atabakhshian, R
   Salami, S
   Mirfakhraie, R
   Khatonabadi, SM
   Sirati-Sabet, M
   Yaghmaei, BG
   Ghafghazi, S
   Beirami, AD
   Rezaei, MS
   Ziai, SA
AF Atabakhshian, Roya
   Salami, Siamak
   Mirfakhraie, Reza
   Khatonabadi, Somayeh Mahmoodi
   Sirati-Sabet, Majid
   Yaghmaei, Bahram Gholamali
   Ghafghazi, Shiva
   Beirami, Amirreza Dowlati
   Rezaei, Mitra Sadat
   Ziai, Seyed Ali
TI Umbelliprenin Suppresses Angiogenesis Signaling in SKBR-3 Cell Line by
   Downregulation of EGF/CoCl2 -Mediated PI3K/AKT/MAPK
SO RESEARCH JOURNAL OF PHARMACOGNOSY
LA English
DT Article
DE angiogenesis; breast cancer; CoCl2; EGF; umbelliprenin
ID CANCER; VEGF; HIF-1-ALPHA; APOPTOSIS; GROWTH; EXPRESSION; INCREASES;
   COUMARINS; TARGETS
AB Background and objectives: Umbelliprenin, a prenylated coumarin from different species of Ferula, has demonstrated anti-cancer effects in various types of cancer cells, but the potential molecular mechanisms for the anti-angiogenic activity of umbelliprenin in breast cancer cells have not yet been studied. In this study, we investigated the possible molecular pathways involved in the antiangiogenic effect of umbelliprenin in EGF and CoCl2 stimulated SKBR-3 breast cancer cells. Methods: Effects of umbelliprenin on the changes in EGFR signaling genes (EGFR, PI3K, AKT, mTOR, S6K, 4EBP1, ERK1/2, HIF-1 alpha, HIF-1 beta, VEGF, VEGFR) and proteins (VEGF/HIF-1 alpha) expression were assayed in SKBR-3 via Quantitative PCR and Western blotting assays. Results: Umbelliprenin dramatically decreased the living cells in a concentration related manner (IC50 =103.9 mu M) and non- toxic doses of umbelliprenin IC5 and IC10 (10 and 20 mu M, respectively) were used for evaluating in vitro anti-angiogenic effects. Umbelliprenin significantly reduced pro-angiogenic AKT, ERK1, ERK2, mTOR, S6K, HIF-1 alpha, HIF-1 beta, VEGF and VEGFR mRNAs in EGF-treated, and AKT, ERK2, S6K, HIF-1 alpha, HIF-1 beta, VEGF and VEGFR mRNAs in CoCl2-treated cells. Umbelliprenin significantly increased anti-angiogenic 4EBP1 mRNA in EGF / CoCl2-treated cells. It significantly decreased the levels of HIF-1 alpha and VEGF proteins, in CoCl2-treated cells. Conclusion: Our findings showed that umbelliprenin exhibits anti-angiogenic effects by decreasing the expression of AKT/mTOR/MAPK angiogenesis pathways in EGF or CoCl2 treated SKBR-3 breast cancer cells.
C1 [Atabakhshian, Roya; Salami, Siamak; Khatonabadi, Somayeh Mahmoodi; Sirati-Sabet, Majid; Yaghmaei, Bahram Gholamali] Shahid Beheshti Univ Med Sci, Sch Med, Dept Clin Biochem, Tehran, Iran.
   [Mirfakhraie, Reza] Shahid Beheshti Univ Med Sci, Sch Med, Dept Med Genet, Tehran, Iran.
   [Ghafghazi, Shiva; Ziai, Seyed Ali] Shahid Beheshti Univ Med Sci, Sch Med, Dept Pharmacol, Tehran, Iran.
   [Beirami, Amirreza Dowlati] Shahid Beheshti Univ Med Sci, Sch Pharm, Dept Med Chem, Tehran, Iran.
   [Rezaei, Mitra Sadat] Shahid Beheshti Univ Med Sci, Sch Med, Dept Pathol, Tehran, Iran.
RP Ziai, SA (corresponding author), Shahid Beheshti Univ Med Sci, Sch Med, Dept Pharmacol, Tehran, Iran.
EM aliziai@sbmu.ac.ir
FU Shahid Beheshti University of Medical Sciences [11214]
FX This research was funded by grant number 11214 from the Shahid Beheshti
   University of Medical Sciences. This article was taken from a thesis
   written by Roya Atabakhshian at the School of Medicine, Shahid Beheshti
   University of Medical Sciences (Registration No: 342).
CR Ahluwalia A, 2012, CURR MED CHEM, V19, P90, DOI 10.2174/092986712803413944
   Al Okail MS, 2010, J SAUDI CHEM SOC, V14, P197, DOI 10.1016/j.jscs.2010.02.005
   Alizadeh MN, 2018, IRAN J PHARM RES, V17, P976
   Barthomeuf C, 2008, PHYTOMEDICINE, V15, P103, DOI 10.1016/j.phymed.2007.04.001
   Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373
   Chakrabarti J, 2004, BRIT J CANCER, V91, P954, DOI 10.1038/sj.bjc.6602059
   Changavi Arathi A, 2015, J Lab Physicians, V7, P79, DOI 10.4103/0974-2727.163129
   Eales KL, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.50
   Folkman J, 2006, ANNU REV MED, V57, P1, DOI 10.1146/annurev.med.57.121304.131306
   Guru SK, 2015, CANCER RES, V75, P2886, DOI 10.1158/0008-5472.CAN-14-2312
   Iranshahi M, 2008, PLANTA MED, V74, P147, DOI 10.1055/s-2008-1034293
   Iranshahi M, 2018, AVICENNA J PHYTOMEDI, V8, P296
   Iranshahi M, 2010, PHARM BIOL, V48, P217, DOI 10.3109/13880200903019226
   Kerbel RS, 1997, NATURE, V390, P335, DOI 10.1038/36978
   Khaghanzadeh N, 2012, DARU, V20, P1
   Khong T. L., 2013, BMC CANCER, V13, P1
   Kim MH, 2017, ONCOL REP, V37, P777, DOI 10.3892/or.2016.5296
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Lee JW, 2004, EXP MOL MED, V36, P1, DOI 10.1038/emm.2004.1
   Li N, 2019, BRIT J CANCER, V120, P703, DOI 10.1038/s41416-019-0383-z
   Li Q, 2018, ONCOL LETT, V15, P1119, DOI 10.3892/ol.2017.7369
   Li S, 2015, SCI REP, V5, P14417
   Liu ZJ, 2015, J ZHEJIANG UNIV-SC B, V16, P32, DOI 10.1631/jzus.B1400221
   Mojsilovic-Petrovic J, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-12
   Mousavi SH, 2015, AVICENNA J PHYTOMEDI, V5, P520
   Nakai K, 2016, AM J CANCER RES, V6, P1609
   Nielsen DL, 2010, BREAST CANCER RES, V12, P1
   Paplomata E, 2014, THER ADV MED ONCOL, V6, P154, DOI 10.1177/1758834014530023
   Park JH, 2016, PHYTOMEDICINE, V23, P1716, DOI 10.1016/j.phymed.2016.10.010
   Peng XH, 2006, J BIOL CHEM, V281, P25903, DOI 10.1074/jbc.M603414200
   Rabe SZT, 2016, J IMMUNOTOXICOL, V13, P209, DOI 10.3109/1547691X.2015.1043606
   Rashidi M, 2018, J CELL PHYSIOL, V233, P8908, DOI 10.1002/jcp.26814
   Rashidi M, 2017, IN VITRO CELL DEV-AN, V53, P7, DOI 10.1007/s11626-016-0080-7
   Rashidi M, 2016, IRAN RED CRESCENT ME, V18, DOI 10.5812/ircmj.35167
   Saryeddine L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165876
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Shakeri A, 2014, J ASIAN NAT PROD RES, V16, P884, DOI 10.1080/10286020.2014.917630
   Shi YH, 2010, ONCOL LETT, V1, P657, DOI 10.3892/ol_00000115
   Soggia A, 2014, DIABETOLOGIA, V57, P2348, DOI 10.1007/s00125-014-3365-y
   Vengellur A, 2004, TOXICOL SCI, V82, P638, DOI 10.1093/toxsci/kfh278
   Ziai SA, 2012, IRAN J PHARM RES, V11, P653
NR 41
TC 0
Z9 0
U1 0
U2 0
PU IRANIAN SOC PHARMACOGNOSY
PI TEHRAN
PA NO 8 SHAMS ALLEY, VALI-E-ASR ST, TEHRAN, 00000, IRAN
SN 2345-4458
EI 2345-5977
J9 RES J PHARMACOGN
JI Res. J. Pharmacogn.
PD WIN
PY 2021
VL 8
IS 1
BP 7
EP 18
DI 10.22127/rjp.2020.119314
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA PM2OU
UT WOS:000603646200002
OA DOAJ Gold
DA 2021-01-23
ER

EF